National Bank of Canada’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
National Bank of Canada's XBI Position: Q1 2026 in Review
National Bank of Canada reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 0.29% in Q1 2026, selling an estimated $13.2K and leaving 37,018 shares worth $4.73M. The position accounts for ﹤0.01% of the portfolio, ranked #871.
National Bank of Canada first reported a position in XBI in Q4 2021 and has held it in 18 quarters since. The position peaked at $44.5M in Q1 2022. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- National Bank of Canada held 37,018 shares of State Street SPDR S&P Biotech ETF worth $4.73M as of Q1 2026.
- National Bank of Canada sold 106 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $13.2K.
- State Street SPDR S&P Biotech ETF made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #871 holding.
- National Bank of Canada first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and has held it in 18 quarters since.
- National Bank of Canada's State Street SPDR S&P Biotech ETF position peaked at $44.5M in Q1 2022.
- 815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.